ArticleClinical pharmacology and therapeutics2022
Serotonin-Affecting Antidepressant Use in Relation to Platelet Reactivity.
Article in Clinical pharmacology and therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Polygenic risk of major depressive disorder as a risk factor for venous thromboembolism.Blood advances · 2023Pooled it
- Selective serotonin re-uptake inhibitors and risks of post-operative hematoma after elbow fracture surgery.JSES international · 2026Article
- Altered platelet function in persistent depressive disorder: a study of density subpopulations and fibrinogen binding.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Altered platelet function in persistent depressive disorder: a study of density subpopulations and fibrinogen binding.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Haemorrhagic event reporting with concomitant gemcitabine and warfarin: a VigiBase disproportionality analysis.Frontiers in pharmacology · 2026Article
- First trimester antidepressant use and miscarriage: a population-based cohort study using Clinical Practice Research Datalink GOLD.The British journal of general practice : the journal of the Royal College of General Practitioners · 2025Article
- Use of serotonergic antidepressants and perioperative complications in patients undergoing lower limb arthroplasty: Systematic review and meta-analysis of comparative studies.Journal of orthopaedics · 2025Review
- Clinical Implications of Antidepressants and Associated Risk of Bleeding: A Narrative Review.Current pain and headache reports · 2025Review
- Postural orthostatic tachycardia syndrome in post-COVID-19 long-hauler patients is associated with platelet storage pool deficiency.Frontiers in medicine · 2025Article
- Nonvitamin K Anticoagulants: Risk of Bleeding When Interacting With Other Medications: A Cohort Study From Medicare.Clinical cardiology · 2024Observational
- A Biobehavioral Perspective on Caring for Allogeneic Hematopoietic Stem Cell Transplant Survivors with Graft-Versus-Host Disease.Transplantation and cellular therapy · 2024Article
- Obstructive Sleep Apnea, Platelet Aggregation, and Cardiovascular Risk.Journal of the American Heart Association · 2024Article
- The association between levels of brain-derived neurotrophic factor and comorbid depression in patients with cardiovascular disease: The Framingham Heart Study.Psychiatry and clinical neurosciences · 2024Article
- The study of platelet aggregation using a microtiter plate reader ‒ methodological considerations.Pharmacological reports : PR · 2024Review
- Heterogeneity of platelets and their responses.Research and practice in thrombosis and haemostasis · 2024Article
- Sertraline in depressed patients with or at risk for coronary heart disese: a systemic review.American journal of cardiovascular disease · 2024Review
- Article
- Selective serotonin reuptake inhibitor use, age-related neuropathology and cognition in late-life.Psychiatry research · 2023Article
- The association between platelet reactivity and lipoprotein levels in Framingham Heart Study participants.Thrombosis research · 2023Article
- Association between depression and macrovascular disease: a mini review.Frontiers in psychiatry · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
Abstract
Depression is an independent risk factor of cardiovascular disease morbidity. Serotonin is a key neurotransmitter in depressive pathology, contained within platelets, and is a weak activator of platelets. Our study assessed the link between platelet reactivity traits, depression, and antidepressant (AD) use in a large population sample. Our study was conducted in the Framingham Heart Study (n = 3,140), and AD use (n = 563) and aspirin use (n = 681) were noted. Depression was measured using the Center for Epidemiological Studies-Depression (CES-D) survey. Platelet reactivity traits were measured across multiple agonists using five distinct assays. We utilized a linear mixed effects model to test associations between platelet traits and depression, adjusting for age, sex, aspirin use, and AD use. Similarly, we analyzed trait associations with any AD use, serotonin-affecting ADs, and norepinephrine-affecting ADs, respectively. There were strong associations with reduced platelet function and AD use, particularly with serotonin-affecting medications. This included lower Optimul epinephrine maximal aggregation (P = 4.87E-13), higher U46619 half maximal effective concentration (P = 9.09E-11), lower light transmission aggregometry (LTA) adenosine diphosphate (ADP) final aggregation (P = 1.03E-05), and higher LTA ADP disaggregation (P = 2.28E-05). We found similar associations with serotonin-affecting ADs in an aspirin-taking subset of our sample. There were no significant associations between platelet traits and depression. In the largest study yet of AD use and platelet function we show that antidepressants, particularly serotonin-affecting ADs, inhibit platelets. We did not find evidence that depressive symptomatology in the absence of medication is associated with altered platelet function. Our results are consistent with AD use leading to platelet serotonin depletions, decreased stability of platelet aggregates, and overall decreased aggregation to multiple agonists, which may be a mechanism by which ADs increase risk of bleeding and decrease risk of thrombosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.